Learn More
PurposeThe CC-chemokine ligand 2 (CCL2) is highly expressed in various malignancies and promotes carcinogenesis. Blocking CCL2 has preclinical antitumor activity. A phase 1 trial of carlumab (CNTO(More)
3009 Background: Akt mediates cell proliferation, survival, and angiogenesis and is deregulated in cancer. MK is a potent, allosteric Akt1/2/3 inhibitor, with wide preclinical antitumor activity and(More)